While Abraham was designing compounds to bind to the surface cavities of Hb, the research group from Burroughs Wellcome led by Peter Goodford was also actively developing antisickling aromatic aldehydes to treat SCD (Beddell et al., 1984; Kneen, 1985; Merrett et al., 1986). Here, GSTM1 is linked to Schnyder corneal dystrophy.